4.10.23.1Vertical

Asthma & Allergy-Pulmonology Programs

Practices jointly managing asthma and pulmonary allergy conditions.

Market snapshot

These figures describe Pulmonology & Respiratory Medicine (4.10.23), the segment that Asthma & Allergy-Pulmonology Programs sits within — not Asthma & Allergy-Pulmonology Programs on its own.

FragmentationFragmentedEstimate

Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so pulmonology is not separately sized.

Business model & economics

Revenue model

Office, diagnostic, and procedure reimbursement

Key economics

Recurring revenue
Moderate

chronic respiratory care recurs

EBITDA margin
15–25%
Capex intensity
Low

Characteristics

  • Chronic respiratory disease and aging drive demand.
  • Sleep medicine and infusion as ancillaries.
  • Less consolidated, with emerging MSO interest.

M&A deal context

Deal activityModerate

Who’s acquiring

  • Emerging pulmonology MSO platforms
  • Multispecialty groups
  • Sleep- and infusion-aligned acquirers

What’s driving deals

  • Emerging pulmonology consolidation.
  • Chronic-respiratory and aging demand.
  • Ancillary sleep and infusion economics.

Find Asthma & Allergy-Pulmonology Programs acquisition targets

Search Acquisera’s index for companies classified under Asthma & Allergy-Pulmonology Programs (4.10.23.1) and build a targeted deal pipeline.

Search companies